Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Stopped PI closed study early, all patients experienced severe toxicities and progressed

Conditions

• Hormone-sensitive Metastatic Breast Cancer

Interventions

• DRUG: OSI-906
• DRUG: Erlotinib
• DRUG: Letrozole
• DRUG: Goserelin

Sponsor

Vanderbilt-Ingram Cancer Center